2 min read

EverHint Signal — Momentum Swing: Aggressive Momentum — November 24, 2025

Aggressive Momentum fired four breakout signals today, each showing strong momentum, elevated volatility, and above-average volume. Market tone was risk-on with small-caps leading and VIX easing, but conditions remain volatile. This is an experimental scanner.

What This Signal Is (Quick)

Aggressive Momentum targets the triple-threat setups:
high momentum + high volume + high volatility.

This strategy hunts for stocks:

  • pushing toward highs
  • supported by expanding volume
  • exhibiting 50%+ annualized volatility
  • showing clear institutional participation

The signal type is breakout — momentum continuation, not dip buying. Movements can be fast, sharp, and emotional, making this a high-risk / high-reward swing strategy.

Holding window: 1–4 weeks
Scanner status: experimental


How We Ranked Today (Reader Version)

Ranking uses:

  1. Composite score (0–1 scale → displayed as 0–100)
  2. If tied: volume thrust
  3. If tied: adv20 (liquidity)

Overlays applied:

  • Net insider activity (P–S transactions from last 90 days)
  • Earnings proximity (days → earnings, calculated from earnings calendar)
  • Analyst coverage & EPS/revenue estimates
  • Market context (indices, VIX, yields from markets snapshot)

Today’s scan returned four total signals.


🔥 Breakout Signals — November 24, 2025

Ranked by composite score (0–100)
(When all scores are equal → ranked by volume thrust)

Rank Ticker Company Sector Last ($) Vol Thrust % of 52W High Score Market Cap Insider Net (USD) Days → Earnings
1 EXAS Exact Sciences Corp Healthcare 100.90 2.37× 100% 0 19.1B –1.30M 86 (amc)
2 IDXX IDEXX Laboratories Healthcare 725.91 1.58× 95% 0 94.1B 0 54 (amc)
3 GAP Gap Inc Consumer Cyclical 24.96 1.97× 91% 0 9.4B –1.0M 83 (amc)
4 PODD Insulet Corp Healthcare 331.17 1.64× 81% 0 22.0B 0 62 (bmo)

Insider Net Notes

  • EXAS: Several insider sales → –$1.30M
  • GAP: Insider sale → –$1.0M
  • IDXX, PODD: No open-market P/S transactions

Earnings Timing

  • All upcoming earnings are 60–86 days away, meaning low immediate event risk.

Recent Headlines (Summarized)

Using the last 7-day news entries per symbol:

  • EXAS — Exact Sciences
    Coverage focuses on Diagnostics segment expansion and growing demand for screening solutions. Investor discussions highlight resilience in the oncology testing pipeline.
  • IDXX — IDEXX Laboratories
    Recent articles emphasize strength in Veterinary Diagnostics and strong recurring consumables demand.
  • GAP — Gap Inc
    Headlines mention early holiday-season foot-traffic trends and performance variability across brands.
  • PODD — Insulet Corp
    News highlights innovation in insulin delivery systems and competitive positioning in medical tech.

Field Notes

Volume Thrust

  • EXAS: 2.37× — strongest buying pressure today
  • GAP: 1.97× — strong participation
  • PODD & IDXX: solid, above-average volume

52-Week High Context

  • EXAS at 100% — strongest momentum
  • IDXX at 95%
  • GAP at 91%
  • PODD at 81%

Sector Mix
Healthcare dominates (3 of 4 names), consistent with rotation themes seen in Q4 2025.

Volatility
All tickers meet or exceed the volatility threshold required for aggressive setups.


Vlad’s Take (EverHint)

  • S&P 500 +1.0%, Nasdaq +1.7%, Dow +0.25% → clear risk-on session
  • Russell 2000 +1.8% → strong small-cap participation
  • VIX 20.61 (–9%) → easing, but still elevated
  • 10Y yield (^TNX) slightly lower → supportive for growth
  • Crypto mixed: no sector-impactful moves

With a risk-on session and volatility declining, the breakout setups today look well-aligned with market tone — but volatility still suggests using tiered entries and tight exits.
Healthcare dominance is notable and consistent with November’s rotation behavior.

Aggressive Momentum works best in tapes like this: broad strength, strong liquidity, and rising participation.


Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.

This is not financial advice. Do your own due diligence.
See https://www.everhint.com/disclaimer/
https://www.everhint.com/faqs/